Trevena Q3 2022 Earnings Report
Key Takeaways
Trevena reported a net loss of $15.3 million for Q3 2022. The company's cash balance was $40.4 million as of September 30, 2022, expected to fund operations into Q3 2023. OLINVYK commercialization progressed and positive Phase 1 data was reported for TRV045.
OLINVYK received CMS pass-through reimbursement for ambulatory surgical centers and hospital outpatient settings.
Relationship with Vizient is advancing, enabling efficient resource management.
Positive topline Phase 1 data was reported for TRV045, a novel S1P receptor modulator.
Targeted TRV045 proof-of-concept study to assess CNS activity is planned for early 2023.
Trevena
Trevena
Forward Guidance
Trevena expects its cash balance of $40.4 million as of September 30, 2022, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the third quarter of 2023.